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Aims We aimed to evaluate the impact of age on the performance of the European Society of Cardiology (ESC) 0/1h-




We prospectively enrolled patients presenting to the emergency department (ED) with symptoms suggestive of
acute myocardial infarction in three large diagnostic studies. Final diagnoses were adjudicated by two independent
cardiologists. High-sensitivity cardiac troponin (hs-cTn) T and I concentrations were measured at presentation and
after 1 h. Patients were stratified according to age [<55 years (young), >_55 to <70 years (middle-age), >_70 years
(old)]. Rule-out safety of the ESC hs-cTnT 0/1h-algorithm was very high in all age-strata: sensitivity 100% [95% con-
fidence interval (95% CI) 94.9–100] in young, 99.3% (95% CI 96.0–99.9) in middle-age, and 99.3% (95% CI 97.5–
99.8) in old patients. Accuracy of rule-in decreased with age: specificity 97.0% (95% CI 95.8–97.9) in young, 96.1%
(95% CI 94.5–97.2) in middle-age, and 92.7% (95% CI 90.7–94.3) in older patients. Triage efficacy decreased with
increasing age (young 93%, middle-age 80%, old 55%, P < 0.001). Similar results were found for the ESC hs-cTnT
0/1h-algorithm. Alternative, slightly higher cut-off concentrations optimized for older patients maintained very high
safety of rule-out, increased specificity of rule-in (P < 0.01), reduced overall efficacy for hs-cTnT (P < 0.01), while
maintaining efficacy for hs-cTnI. Findings were confirmed in two validation cohorts (n = 2767).
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Conclusion While safety of the ESC 0/1h-algorithms remained very high, increasing age significantly reduced overall efficacy
and the accuracy of rule-in. Alternative slightly higher cut-off concentrations may be considered for older patients,
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Introduction
In patients presenting with symptoms suggestive of acute myocardial
infarction (AMI), rapid identification of AMI as a life-threatening dis-
order, but also rapid and accurate rule-out of AMI has enormous
medical and economic value.1–3 Recently, diagnostic strategies apply-
ing high-sensitivity cardiac troponin (hs-cTn) T or I assays, including
the European Society of Cardiology (ESC) 0/1h-algorithms, have
been developed and facilitate the early triage towards rule-out or
rule-in of AMI.1–11
Beyond the presence or absence of AMI, age seems to be the
most important confounder of hs-cTnT and hs-cTnI blood concen-
trations.12–21 Mildly elevated hs-cTnT and hs-cTnI blood concentra-
tions are common in elderly individuals without apparent ischaemic
symptoms.2,3,12–21 Unfortunately, the impact of age on the
diagnostic performance of the ESC 0/1h-algorithms is incompletely
understood.
To address this major gap in knowledge, we prospectively investi-
gated the impact of age on the performance of the ESC 0/1h-algo-
rithms in a large multicentre diagnostic study using central
adjudication. In a second step, the age-specific findings and aged-
optimized alternative cut-off concentrations for older patients
derived in this multicentre study were externally validated in two
additional diagnostic studies.
Methods
Study design and oversight
We enrolled adult patients presenting with suspected AMI to the
emergency department (ED) in three large prospective diagnostic
studies carried out according to the principles of the Declaration of
Helsinki and approved by the local ethics committees:
Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE, main cohort),5,7–10,17,22–26 Biomarkers in Acute Cardiac
Care (BACC, first validation cohort),27 and High-sensitivity cardiac
Troponin T assay for RAPID rule-out of AMI (TRAPID-AMI, second
validation cohort).28 Written informed consent was obtained from
all patients.
The authors designed the study, gathered, and analysed the data
according to the STARD guidelines29 for studies of diagnostic accuracy
(Supplementary material online, Table S1), vouched for the data and ana-
lysis, wrote the paper, and decided to publish. Routine clinical assessment
and detailed methodological descriptions of all three cohorts are given in
the Supplementary material online.
The ESC high-sensitivity cardiac troponin
Tand high-sensitivity cardiac troponin
I 0/1h-algorithms
The concept of the ESC 0/1h-algorithms is described in detail in the
Supplementary material online and shown in Supplementary material on-
line, Figure S1.
Stratification of patients according to age
We aimed to stratify patients by age into three equally large cohorts.
Based on previous findings from APACE5,8–10,22,25,30–33 we assumed that
the following three age-strata should yield near-equal group-size:
<55 years (young), >_55 to <70 years (middle-age), and >_70 years (old).
Statistical analysis
Safety for rule-out was quantified by the resulting sensitivity [and
negative predictive value (NPV)], accuracy for rule-in was quantified
by the resulting specificity [and positive predictive value (PPV)] for
non-ST-segment elevation myocardial infarction (NSTEMI) and over-
all efficacy was quantified by the percentage of patients triaged either
towards rule-out or rule-in by the respective strategy. Time since
chest pain onset (cpo) was determined at the time of first study blood
draw. In the main cohort, subgroup analyses were performed in early
presenters (cpo <_2 h), late presenters (cpo >6 h), and in very old
patients (age >_80 years).
All hypothesis testing was two-tailed, and P-values of less than 0.05
were considered to indicate statistical significance without adjustments
for multiple testing. Statistical analyses were performed using SPSS for
Windows, version 24.0 (SPSS Inc., Chicago, IL, USA), MedCalc, version
9.6.4.0 (MedCalc Software, Ostend, Belgium), and R (Version 3.3.1,




Study cohort and characteristics of patients
From April 2006 to August 2015, 3123 patients were available for
the analysis of the ESC hs-cTnT 0/1h-algorithm and 2828
patients for the analysis of the ESC hs-cTnI 0/1h-algorithm
(Supplementary material online, Figure S2). Older patients differed
in multiple characteristics from younger and middle-aged patients,
particularly a higher prevalence of pre-existing cardiovascular dis-
orders including AMI and stroke (Table 1, Supplementary material
online, Table S2).























Among patients with complete dataset of hs-cTnT, the adjudicated
final diagnosis was NSTEMI in 491/3123 patients (16%), unstable an-
gina in 301/3123 (10%), cardiac symptoms of origin other than coron-
ary artery disease such as tachyarrhythmia, Takotsubo
cardiomyopathy, heart failure or myocarditis in 476/3123 (15%),
non-cardiac symptoms in 1728/3123 (55%), and unknown in 127/
3123 patients (4%). The prevalence of NSTEMI increased with
increasing age (young 6.4%, middle-aged 15%, and old 27%,
P < 0.001). Distribution of final diagnoses was similar in patients with
complete dataset of hs-cTnI (Supplementary material online).
High-sensitivity cardiac troponin concentrations at
presentation according to age and final diagnoses and
interaction between age and high-sensitivity cardiac
troponin
Concentrations of hs-cTnT and hs-cTnI at presentation showed a
moderate-to-high correlation with age in both datasets (q = 0.6 for
....................................................................................................................................................................................................................











Age (years) 61 (49–74) 45 (37–50) 62 (58–66) 78 (74–82)
Time from cpo to first study blood draw (h) 5 (2–12) 4 (2–11) 5 (2–12) 5 (3–12) <0.001
Male gender, n (%) 2116 (68) 860 (77) 645 (69) 611 (57) <0.001
Risk factors, n (%)
Hypertension 1911 (61) 382 (34) 622 (67) 907 (85) <0.001
Hypercholesterolaemia 1538 (49) 314 (28) 526 (56) 698 (66) <0.001
Diabetes 550 (18) 105 (9) 186 (20) 259 (24) <0.001
Current smoking 782 (25) 457 (41) 244 (26) 81 (8) <0.001
History of smoking 1172 (38) 307 (27) 382 (41) 483 (45) <0.001
History, n (%)
Coronary artery disease 1038 (33) 172 (15) 327 (35) 539 (51) <0.001
Previous myocardial infarction 742 (24) 136 (12) 229 (25) 377 (35) <0.001
Previous revascularization 858 (28) 154 (14) 287 (31) 417 (39) <0.001
Peripheral artery disease 162 (5) 8 (1) 47 (5) 107 (10) <0.001
Previous stroke 174 (6) 9 (1) 46 (5) 119 (11) <0.001
Positive family history 469 (15) 209 (19) 158 (17) 102 (10) <0.001
ECG findings, n (%)
Left bundle branch block 117 (4) 11 (1) 25 (3) 81 (8) <0.001
ST-segment depression 323 (10) 54 (5) 119 (13) 150 (14) <0.001
T-wave inversion 343 (11) 82 (7) 90 (10) 171 (16) <0.001
No significant ECG abnormalities 2276 (73) 902 (80) 674 (72) 700 (66) <0.001
Body mass index (kg/m2) 27 (24–30) 26 (24–30) 27 (24–30) 26 (24–29) <0.001
Laboratory findings
Creatinine clearance (mL/min/m2) 85 (69–101) 98 (85–112) 85 (73–99) 68 (53–83) <0.001
Chronic medication, n (%)
ASA/thienopyridine 1211 (39) 202 (18) 388 (42) 621 (58) <0.001
b-Blockers 1078 (35) 197 (18) 355 (38) 526 (49) <0.001
ACEIs/ARBs 1230 (39) 219 (20) 391 (42) 620 (58) <0.001
Calcium antagonists 467 (15) 61 (5) 141 (15) 265 (25) <0.001
Nitrates 337 (11) 37 (3) 79 (8) 221 (21) <0.001
Statins 1110 (36) 182 (16) 383 (41) 545 (51) <0.001
Diagnostic/therapeutic procedures
Coronary angiography 715 (23) 137 (12) 260 (28) 318 (30) <0.001
PCI 402 (13) 76 (7) 143 (15) 183 (17) <0.001
CABG 60 (2) 7 (1) 22 (2) 31 (3) <0.001
Ergometry 744 (24) 229 (20) 280 (30) 235 (22) <0.001
MPS-SPECT 324 (11) 56 (5) 114 (12) 154 (14) <0.001
Numbers are presented as median (interquartile range) or numbers (%).
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; cpo, chest pain onset;
ECG, electrocardiography; MPS-SPECT, myocardial perfusion scanning-single photon emission computed tomography; PCI, percutaneous coronary angiography.



















..hs-cTnT and q = 0.49 for hs-cTnI, respectively, both P < 0.001). Old
patients had significantly higher hs-cTnT and hs-cTnI concentrations
at presentation than young and middle-aged patients, particularly in
patients with final diagnoses other than NSTEMI (Supplementary ma-
terial online, Figure S3A,B). The interaction between age and hs-cTnT
concentrations for NSTEMI was significant (P < 0.001), but not for
hs-cTnI (P = 0.31) (Supplementary material online; Supplementary
material online, Figure S4A,B).
Diagnostic accuracy of high-sensitivity cardiac troponin T
and high-sensitivity cardiac troponin I
Areas under the curves (AUCs) of hs-cTnT concentrations at presenta-
tion in young, middle-aged, and old patients were 0.96 (95% CI 0.94–
0.98), 0.93 (95% CI 0.91–0.95), and 0.89 (95% CI 0.87–0.91), respectively.
Areas under the curves of hs-cTnI concentrations at presentation in
young, middle-aged, and old patients were 0.95 (95% CI 0.93–0.97), 0.92
(95% CI 0.90–0.94), and 0.87 (95% CI 0.85–0.90), respectively (Figure 1A).
Figure 1 Diagnostic accuracy of high-sensitivity cardiac troponin T and high-sensitivity cardiac troponin I concentrations at presentation to the
emergency department for the diagnosis of non-ST-segment elevation myocardial infarction in patients stratified according to age. Receiver operating
characteristics curve and corresponding areas under the curves indicating diagnostic accuracy of high-sensitivity cardiac troponin T (blue) and high-
sensitivity cardiac troponin I (orange) concentrations at presentation for the diagnosis of acute myocardial infarction in patients stratified according
to age into young (<55 years), middle-age (>_55–<70 years), and old (>_70 years) in (A) main cohort, (B) first validation cohort, and (C) second valid-
ation cohort. hs-cTnT, high-sensitivity cardiac troponin T; hs-cTnI, high-sensitivity cardiac troponin I.































































































Diagnostic performance of the ESC high-sensitivity car-
diac troponin T 0/1h-algorithm according to age
Among 1122 (36%) young patients, 956/1122 [85% (95% CI 83–87)]
were triaged towards rule-out [sensitivity 100% (95% CI 94.9–100),
NPV 100% (95% CI 99.6–100)], 92/1122 [8% (95% CI 7–10)] patients
were triaged towards rule-in [specificity 97.0% (95% CI 95.8–97.9),
PPV 66.3% (95% CI 56.2–75.1)].
Among 935 (30%) middle-aged patients, 606/935 [65% (95% CI
62–68)] were triaged towards rule-out [sensitivity 99.3% (95% CI
96.0–99.9), NPV 99.8% (95% CI 99.1–100)], 141/935 [15% (95%
CI 13–17)] patients triaged towards rule-in [specificity 96.1% (95% CI
94.5–97.2), PPV 78.0% (95% CI 70.5–84.1)].
Among 1066 (34%) old patients, 317/1066 [30% (95% CI 27–33)]
were triaged towards rule-out [sensitivity 99.3% (95% CI 97.5–99.8),
NPV 99.4% (95% CI 97.7–99.8)], 272/1066 [25% (95% CI 23–28)]
patients were triaged towards rule-in [specificity 92.7% (95% CI
90.7–94.3), PPV 79.0% (95% CI 73.8–83.5); Table 2, Figure 2A].
One middle-aged and two old patients with NSTEMI were missed
(Supplementary material online, Table S3). Detailed diagnostic per-
formance of the ESC hs-cTnT 0/1h-algorithm in decades of age is
shown in Figure 2B.
Diagnostic performance of the ESC high-sensitivity car-
diac troponin I 0/1h-algorithm according to age
Overall, similar findings emerged when assessing the diagnostic per-
formance of the ESC hs-cTnI 0/1h-algorithm according to age
(Figure 3, Table 3, Supplementary material online, Table S3).
Derivation of alternative cut-off criteria for the ESC high-
sensitivity cardiac troponin T 0/1h-algorithm
Optimal alternative cut-offs for rule-out were <8 ng/L at presentation
in patients presenting with a cpo >3 h or <12 ng/L at presentation
and an absolute 1h-change <3 ng/L. The safety was identical to the
original ESC hs-cTnT 0/1h-algorithm, but the proportion of patients
eligible for direct rule-out increased from 2.2% (95% CI 1.3–3.1) to
11% (95% CI 8.9–13). The proportion of patients ruled-out overall
was identical to that of the original ESC 0/1h-algorithm. For rule-in,
optimal alternative cut-offs were >_80 ng/L at presentation or an abso-
lute 1h-change >_6 ng/L. These cut-offs improved specificity from
92.7% (95% CI 90.7–94.3) to 96.8% (95% CI 95.3–97.8, P < 0.01) and
PPV from 79.0% (95% CI 73.8–83.5) to 87.8% (95% CI 82.6–91.6,
P = 0.04). However, the proportion of patients ruled-in for NSTEMI
decreased from 25% (95% CI 23–28) to 21% (95% CI 18–24) and
from 18% (95% CI 16–21) to 12% (95% CI 10–14) for direct rule-in;
(Supplementary material online, Table S4A). Accordingly, overall effi-
cacy decreased from 55% to 51% (P < 0.001).
Derivation of alternative cut-off criteria for the ESC high-
sensitivity cardiac troponin I 0/1h-algorithm
Optimal alternative cut-offs for rule-out were <4 ng/L at presentation
in patients presenting with cpo >3 h or <6 ng/L at presentation and
an absolute 1h-change <3 ng/L. The safety was similar to the original
ESC hs-cTnI 0/1h-algorithm (NPV 97.5% vs. 98.1%, P = 0.67), and the
proportion of patients eligible for rule-out increased from 25% (95%
CI 22–27) to 32% (95% CI 29–35) and for direct rule-out from 1.4%
(95% CI 0.7–2.4) to 12% (95% CI 10–14) (Supplementary material
online, Table S4B). For rule-in, optimal alternative cut-offs were
>_100 ng/L at presentation or an absolute 1h-change >_8 ng/L. These
cut-offs significantly improved specificity from 86.4% (95% CI 83.7–
88.7) to 90.6% (95% CI 88.3–92.5, P = 0.01), while the increase in
PPV did not reach statistical significance 67.9% (95% CI 62.4–72.9) to
74.2% (95% CI 68.6–79.2, P = 0.11). Again, the proportion of patients
ruled-in for NSTEMI decreased from 31% (95% CI 28–34) to 27%
(95% CI 24–30) and from 23% (95% CI 20–25) to 16% (95% CI 14–
19) for direct rule-in; (Table 3, Supplementary material online, Table
S4B). Accordingly, overall efficacy increased from 56% to 58%
(P < 0.03).
Sex-specific cut-off criteria for the ESC 0/1h-algorithms
for use in older patients
The diagnostic performance of derived and validated sex-specific cut-
off combinations for use in older patients is shown in the
Supplementary material online and Supplementary material online,
Table S5A–C.
Subgroup analyses in very early presenters, late
presenters, and very old patients
Among 3123 patients with hs-cTnT, 830/3123 patients (27%) pre-
sented within 2 h from cpo. For example, in old patients (n = 226),
64/226 (28%) were ruled-out (sensitivity 98.5%), 62/226 (27%) ruled-
in (specificity 91.1%), and the remaining 100/226 (44%) patients clas-
sified as observe (Supplementary material online, Figure S5A). Similar
results were obtained for hs-cTnI (Supplementary material online,
Figure S5B). The performance of both ESC hs-cTn 0/1h-algorithms in
late presenters and very old patients (age >_80 years) is given in the
Supplementary material online.
Prognostic performance of the ESC high-sensitivity car-
diac troponin T/I 0/1h-algorithms to predict death during
follow-up
Survival of young patients triaged towards rule-out, observe and rule-
in was 100% at 30-days for all age groups and 99.6%, 96.6%, and
95.1% at 2-years, respectively (all P < 0.001). Among middle-aged
patients, survival was 99.8%, 98.4%, and 100% at 30-days, and 99.1%,
93.1%, and 96.8% at 2-years, respectively (all P < 0.001, P = 0.06 for
comparison between observe and rule-in). Among old patients, sur-
vival was 99.7%, 98.7%, and 94.5% at 30-days, and 93.6%, 82.2% and
75.4% at 2-years, respectively (all P < 0.001; Supplementary material
online, Figure S6A).
Similar findings emerged when assessing the prognostic perform-
ance of the ESC hs-cTnI 0/1h-algorithm (Supplementary material on-
line, Figure S6B) and for the prediction of major adverse cardiac
events within 30 days (Supplementary material online).
Validation cohorts
Overall, the characteristics of patients in validation cohort 1 and val-
idation cohort 2 were similar to those of the main cohort
(Supplementary material online, Tables S6 and S7).












































..Diagnostic accuracy of high-sensitivity cardiac troponin T
Areas under the curves of hs-cTnT and hs-cTnI concentrations at
presentation in young, middle-aged, and old patients in both valid-
ation cohorts were similar to AUCs in the main cohort (Figure 1B,C).
Diagnostic performance of the official ESC high-
sensitivity cardiac troponin 0/1h-algorithms and valid-
ation of the alternative cut-off criteria in old patients
In both validation cohorts, findings for the ESC hs-cTnT 0/1h-algo-
rithm (and for the hs-cTnI 0/1h-algorithm in the first validation co-
hort) were similar to the findings of the main cohort. While safety
remained high in older patients, specificity among patients triaged to-
wards rule-in and particularly overall efficacy decreased with increas-
ing age (Figure 4, Tables 4–6, Supplementary material online, Figures
7–9).
Prognostic performance of the ESC high-sensitivity
cardiac troponin 0/1h-algorithms to predict death during
follow-up
Prognostic performance of the ESC 0/1h-algorithms in both valid-
ation cohorts was similar to the prognostic performance in the main
cohort (Supplementary material online; Supplementary material on-
line, Figure S10).
Discussion
This large multicentre study quantified the impact of age on the per-
formance of the ESC 0/1h-algorithms. In a second step, we derived
and externally validated alternative cut-off criteria optimized for the
use in older patients. We report eight major findings:
First, increasing age was associated with a higher prevalence of
pre-existing cardiovascular disorders. Second, while patients adjudi-
cated to have NSTEMI had comparable hs-cTnT and hs-cTnI concen-
trations among the three age-strata, hs-cTnT, and hs-cTnI
concentrations were significantly higher in older patients with other
causes of acute chest discomfort. This finding seems at least in part
explained by the higher prevalence of pre-existing cardiovascular dis-
orders and their association with chronic myocardial injury in older
patients. Third, accordingly the overlap in hs-cTnT and hs-cTnI con-
centrations between NSTEMI and other causes of acute chest dis-
comfort was larger resulting in a lower AUC with increasing age. The
interaction term (hs-cTn*age) for NSTEMI was statistically significant
when using hs-cTnT, but not when using hs-cTnI, possibly suggesting
different effects of aging on hs-cTnT vs. hs-cTnI concentrations.
Fourth, the prevalence of NSTEMI increased substantially with
increasing age and was more than four times higher in older vs.
younger patients. Fifth, age had a major impact on the overall diagnos-
tic performance of the ESC 0/1h-algorithm: while safety as quantified
Figure 2 Diagnostic performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm according to age in the main cohort. Diagnostic
performance of the ESC high-sensitivity cardiac troponin T 0/1h-algorithm in patients stratified according to age into (A) young, middle-age, old, and
(B) decades. aIf chest pain onset >3 h; D, unsigned change within the first hour; hs-cTnT, high-sensitivity cardiac troponin T; NPV, negative predictive
value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value; Prev., prevalence; Sens., sensitivity; Spec., specificity.




























..by sensitivity and NPV was very high in all age-strata, the percentage
of patients assigned towards rule-out, the specificity among patients
triaged towards rule-in, and particularly overall efficacy decreased
with increasing age. As a consequence, the percentage of old patients
remaining in the observe zone and usually requiring additional diag-
nostic testing including a 3h-sample of hs-cTn and cardiac imaging
was nearly twice as high as in middle-aged and more than four times
as high as in young patients. Due to the increase in AMI prevalence
with age, PPV remained high in older patients. Sixth, use of individual-
ized slightly higher cut-offs in older patients maintained very high
safety of rule-out, increased specificity of rule-in, reduced overall effi-
cacy for hs-cTnT, while maintaining efficacy for hs-cTnI. Accordingly,
the use of slightly higher cut-off concentrations may be considered,
particularly if using hs-cTnI. Still, the overall improvement achieved
was modest and needs to be balanced against the increased complex-
ity created by specific cut-offs in elderly patients. Using sex-specific
cut-off criteria vs. modified cut-off criteria in older patients did not
further increase the overall diagnostic performance of both ESC 0/
1h-algorithms. Beyond age, also the time from cpo, sex, and renal
function have been shown to affect hs-cTnT and hs-cTnI concentra-
tions. Although preliminary evidence suggests that the effect of these
additional confounders overall is smaller as compared to that of
age,1,2,12,15,34 computerized integration of all confounders might be
the most accurate approach once convenient physician-information
technology interfaces become available. Seventh, while the vast ma-
jority of findings for the ESC 0/1h-algorithm using hs-cTnI mirrored
the findings for the ESC 0/1h-algorithm using hs-cTnT, safety of rule-
out and accuracy of rule-in were slightly lower for hs-cTnI as
Figure 2 Continued.
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Table 2 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged and old patients and of alternative
cut-off criteria in old patients in the main cohort














Prevalence of NSTEMI 72 (6) 137 (15) 282 (27) <0.001 <0.001 282 (27) 1
Sensitivity of rule-out 100% (94.9–100) 99.3% (96.0–99.9) 99.3% (97.5–99.8) 0.47 0.98 99.3% (97.5–99.8) 1
NPV of rule-out 100% (99.6–100) 99.8% (99.1–100) 99.4% (97.7–99.8) 0.21 0.24 99.4% (97.8–99.8) 0.27
Specificity of rule-in 97.0% (95.8–97.9) 96.1% (94.5–97.2) 92.7% (90.7–94.3) 0.27 <0.01 96.8% (95.3–97.8) <0.001
PPV of rule-in 66.3% (56.2–75.1) 78.0% (70.5–84.1) 79.0% (73.8–83.5) 0.05 0.81 87.8% (82.6–91.6) <0.001
Rule-out, n (%)
Based on 0h- and 1h-sample 956 (85) 606 (65) 317 (30) <0.001 <0.001 317 (30) 1
Based on 0h-sample onlyd 305 (27) 128 (14) 23 (2) <0.001 <0.001 113 (11) <0.001
Rule-in, n (%)
Based on 0h- and 1h-sample 92 (8.2) 141 (15) 272 (25) <0.001 <0.001 224 (21) <0.001
Based on 0h-sample only 44 (3.9) 86 (9) 195 (18) <0.001 <0.001 131 (12) <0.001
Overall efficacy 1048 (93) 747 (80) 589 (55) <0.001 <0.001 544 (51) <0.001
Prevalence of NSTEMI in the
observational group
11 (15) 26 (14) 65 (14) 0.83 0.95 87 (17) <0.001
Numbers are presented as numbers (%) and percentage with 95% confidence interval.
NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.
aP-value for differences between young and middle-aged patients.
bP-value for differences between middle-aged and old patients.
cP-value for differences between official and alternative cut-off criteria in old patients.
dChest pain onset >3 h.
Figure 3 Diagnostic performance of the ESC high-sensitivity cardiac troponin I 0/1h-algorithm according to age in the main cohort. Diagnostic per-
formance of the ESC high-sensitivity cardiac troponin I 0/1h-algorithm in patients stratified according to age into (A) young, middle-age, old, and (B)
decades. aIf chest pain onset >3 h; D, unsigned change within the first hour; hs-cTnI, high-sensitivity cardiac troponin I; NPV, negative predictive value;
NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value; Prev., prevalence; Sens., sensitivity; Spec., specificity.

























..compared to hs-cTnT. At first glance, this finding is surprising as both
assays seem to have comparable diagnostic accuracy for NSTEMI,23
and hs-cTnI-Architect seems to have even higher analytical sensitivity
as compared to hs-cTnT-Elecsys.35 This finding is therefore more
likely related to the inherent verification bias in favour of hs-cTnT
(available among many other information for the adjudication) as
compared to hs-cTnI (not available for the adjudication) and the rare,
but previously described analytical discrepancies between hs-cTnI
and hs-cTnT.8,31 Eighth, irrespective of age, patients triaged towards
rule-out had very high 30-day survival rates of 99–100%. As
expected, 30-day and 1-year or 2-year survival rates were lower in
older patients as compared to younger patients.
Our findings extend and corroborate data previously obtained for
the diagnostic performance of the ESC 0/1h-algorithm assessed in all-
comers with acute chest discomfort.7,8,10,22,33 These findings also ex-
tend and corroborate more general observations made for the use
of hs-cTn in elderly patients.36
The clinical utility of the ESC 0/1h-algorithms also remained
high in very old patients (>_80 years) and those presenting very
early after cpo. While patients presenting early to the ED were
more frequently ruled-in by significant 1h-delta changes, late pre-
senters were primarily ruled-in due to markedly elevated cardiac
troponin (cTn) concentrations. This can be explained by the fact
that the increase in cTn concentrations is time-dependent. Due to
Figure 3 Continued.
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Table 3 Performance of the ESC hs-cTnI 0/1h-algorithm in young, middle-aged and old patients and of alternative
cut-off criteria in old patients in the main cohort














Prevalence of NSTEMI 64 (6.3) 126 (15%) 259 (27%) <0.001 <0.001 259 (27%) 1
Sensitivity of rule-out 98.4% (91.7–99.7) 100% (97.0–100) 97.7% (95.0–98.9) 0.16 0.08 97.7% (95.0–98.9) 1
NPV of rule-out 99.9% (99.3–100) 100% (99.2–100) 97.5% (94.7–98.9) 0.45 <0.01 98.1% (95.8–99.1 0.02
Specificity of rule-in 93.7% (92.0–95.1) 90.8% (88.5–92.8) 86.4% (83.7–88.7) 0.02 0.26 90.6% (88.3–92.5) <0.001
PPV of rule-in 48.7% (39.8–57.7) 62.9% (55.5–69.7) 67.9% (62.4–72.9) 0.03 0.01 74.2% (68.6–79.2) <0.001
Proportion ruled-out
Based on 0h- and 1h-sample 771 (76) 448 (54) 240 (25) <0.001 <0.001 305 (31) <0.001
Based on 0h-sample onlyd 178 (18) 66 (7.9) 14 (1.4) <0.001 <0.001 118 (12) <0.001
Proportion ruled-in
Based on 0h- and 1h-sample 117 (12) 175 (21) 302 (31) <0.001 <0.001 260 (27) <0.001
Based on 0h-sample only 79 (7.8) 120 (14) 219 (23) <0.001 <0.001 159 (16) <0.001
Overall efficacy 890 (87) 623 (75) 543 (56) <0.001 <0.001 566 (58) 0.03
Prevalence of NSTEMI in the
observational group
6 (5) 16 (8) 48 (11) <0.001 <0.001 60 (15) 0.002
Numbers are presented as n (%) and percentage with 95% confidence interval.
NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.
aP-value for differences between young and middle-aged patients.
bP-value for differences between middle-aged and old patients.
cP-value for differences between official and alternative cut-off criteria in old patients.
dChest pain onset >3 h.
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Table 4 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged, and old patients and of alternative
cut-off criteria in old patients in first validation cohort













Prevalence of NSTEMI 41 (9) 99 (23) 147 (24) <0.001 0.79 147 (24) 1
Sensitivity of rule-out 100% (91.4–100) 98.0% (92.9–99.4) 100% (97.5–100) 0.36 0.08 99.3% (96.2–99.9) 0.32
NPV of rule-out 100% (98.9–100) 99.1% (96.8–99.8) 100% (97.7–100) 0.08 0.23 99.4% (96.6–99.9) 0.32
Specificity of rule-in 96.3% (94.0–97.7) 92.0% (88.6–94.5) 87.6% (84.3–90.3) 0.01 0.04 93.4% (90.7–95.3) <0.001
PPV of rule-in 68.0% (54.2–79.2) 75.0% (65.9–82.3) 66.1% (58.7–72.8) 0.36 0.12 77.2% (69.5–83.5) <0.001
Rule-out, n (%)
Based on 0h- and 1h-sample 352 (75) 223 (52) 161 (26) <0.001 <0.001 161 (26) 1
Based on 0h-sample onlyd 28 (6) 6 (1) 4 (1) <0.001 0.22 12 (2) 0.01
Rule-in, n (%)
Based on 0h- and 1h-sample 50 (11) 104 (24) 171 (28) <0.001 0.22 136 (22) <0.001
Based on 0h-sample only 25 (5) 66 (16) 101 (16) <0.001 0.68 74 (12) <0.001
Overall efficacy 402 (86) 327 (76) 332 (54) 0.001 <0.001 298 (48) <0.001
Prevalence of NSTEMI in the
observational group
7 (10) 19 (19) 34 (12) 0.13 0.08 42 (13) 0.008
Numbers are presented as numbers (%) and percentage with 95% confidence interval.
NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.
aP-value for differences between young and middle-aged patients.
bP-value for differences between middle-aged and old patients.
cP-value for differences between official and alternative cut-off criteria in old patients.
dChest pain onset >3 h.
















the higher prevalence of NSTEMI, PPV in older patients was
even higher (70–80%) as in younger patients, and in a range that
most experts consider an acceptable likelihood to initiate invasive
management in the majority of these patients. The additional
use of short-term changes as criteria within the ESC 0/1h-
algorithms at least in part was able to compensate for the substan-
tially lower specificity of mild elevations in hs-cTn in older
patients.36
The lower efficacy observed in older patients is not unique to the
ESC 0/1h-algorithms, but seems to be a universal phenomenon of all
Figure 4 Diagnostic performance of modified cut-off criteria for use in older patients (>_70 years) in all three study cohorts. Diagnostic perform-
ance of the (A) ESC high-sensitivity cardiac troponin T 0/1h-algorithm and (B) ESC high-sensitivity cardiac troponin I 0/1h-algorithm using modified
cut-off criteria for use in older patients (>_70 years). Red numbers indicate modified cut-off values that differ from the official cut-off criteria.
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Table 6 Performance of the ESC hs-cTnI 0/1h-algorithm in young, middle-aged and old patients and of alternative
cut-off criteria in old patients in first validation cohort














Prevalence of NSTEMI 41 (9) 94 (23) 138 (24) <0.001 0.66 138 (24) 1
Sensitivity of rule-out 100% (91.4–100) 97.9% (92.6–99.4) 99.3% (96.0–99.9) 0.35 0.35 97.8% (93.8–99.3) 0.16
NPV of rule-out 100% (98.5–100) 98.5% (94.6–99.6) 98.9% (94.2–99.8) 0.05 0.77 97.8% (93.7–99.2) 0.28
Specificity of rule-in 93.5% (90.8–95.5) 88.9% (85–91.9) 85.8% (82.1–88.8) 0.03 0.30 91.5% (88.5–93.8) <0.001
PPV of rule-in 58.5% (46.3–69.6) 69.6% (60.6–77.2) 65.3% (57.9–72.0) 0.13 0.45 73.4% (65.5–80.0) <0.001
Proportion ruled-out
Based on 0h- and 1h-sample 243 (53) 131 (32) 94 (16) <0.001 <0.001 133 (23) <0.001
Based on 0h-sample onlyd 16 (4) 7 (2) 7 (1) 0.10 0.53 17 (3) 0.01
Proportion ruled-in
Based on 0h- and 1h-sample 65 (14) 115 (28) 170 (30) <0.001 0.57 139 (24) <0.001
Based on 0h-sample only 36 (8) 74 (18) 94 (16) <0.001 0.51 73 (13) <0.001
Overall Efficacy 313 (68) 246 (60) 264 (46) 0.01 <0.001 274 (48) 0.29
Prevalence of NSTEMI in the
observational group
3 (2) 12 (7) 26 (8) 0.03 0.67 33 (11) 0.07
Numbers are presented as n (%) and percentage with 95% confidence interval.
NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.
aP-value for differences between young and middle-aged patients.
bP-value for differences between middle-aged and old patients.
cP-value for differences between official and alternative cut-off criteria in old patients.
dChest pain onset >3 h.
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Table 5 Performance of the ESC hs-cTnT 0/1h-algorithm in young, middle-aged and old patients and of alternative
cut-off criteria in old patients in second validation cohort














Prevalence of NSTEMI 21 (5) 53 (13) 66 (16) <0.001 0.3 66 (16) 1
Sensitivity of rule-out 100% (84.5–100) 90.6% (79.7–95.9) 98.5% (91.9–99.7) 0.14 0.05 98.5% (91.9–99.7) 1
NPV of rule-out 100% (98.9–100) 98.3% (96.0–99.3) 99.4% (96.6–99.9) 0.01 0.3 99.4% (96.7–99.9) 0.41
Specificity of rule-in 96.0% (93.6–97.5) 94.7% (91.9–96.6) 91.1% (87.7–93.6) 0.12 <0.01 94.2% (91.2–96.1) <0.001
PPV of rule-in 51.5% (35.2–67.5) 63.5% (49.9–75.2) 59.0% (47.9–69.2) 0.22 0.61 65.6% (53.0–76.3) 0.04
Rule-out, n (%)
Based on 0h- and 1h-sample 362 (86) 287 (70) 164 (39) <0.001 <0.001 164 (39) 1
Based on 0h-sample onlyd 63 (15) 43 (10) 25 (6) 0.05 <0.001 52 (12) <0.001
Rule-in, n (%)
Based on 0h- and 1h-sample 33 (8) 52 (13) 78 (18) 0.02 0.02 61 (14) <0.001
Based on 0h-sample only 17 (4) 38 (9) 44 (10) 0.003 0.6 26 (6) <0.001
Overall efficacy 395 (94) 340 (83) 243 (57) <0.001 <0.001 227 (53) 0.001
Prevalence of NSTEMI in the
observational group
4 (15) 15 (21) 19 (10) 0.53 0.03 25 (13) 0.03
Numbers are presented as numbers (%) and percentage with 95% confidence interval.
NPV, negative predictive value; NSTEMI, non-ST-segment elevation myocardial infarction; PPV, positive predictive value.
aP-value for differences between young and middle-aged patients.
bP-value for differences between middle-aged and old patients.
cP-value for differences between official and alternative cut-off criteria in old patients.
dChest pain onset >3 h.































































































currently available diagnostic algorithms.2,3,37 The higher prevalence
of cardiovascular comorbidities in older patients invariably reduces
the diagnostic performance of clinical assessment, the electrocardiog-
raphy (ECG), hs-cTn, and cardiac imaging.2,3,37
The exact pathophysiological mechanisms resulting in cardiomyo-
cyte injury in the aging heart are incompletely understood, but seem
to include the effect of pre-existing cardiovascular disorders such as
previous AMI, hypertensive heart disease, as well as myocardial
fibrosis.2,3,38
It is important to highlight that irrespective of the use of the uni-
form or individualized cut-offs in older patients, the ESC 0/1h-algo-
rithms should always be used in conjunction with full clinical
assessment and the ECG. Accordingly, the final sensitivity achieved
by the combination of both ESC 0/1h-algorithms with clinical assess-
ment and the ECG will be even slightly higher as that reported for
the ESC 0/1h-algorithms only. Vice versa, efficacy will be slightly
lower as the clinician will overrule the triage recommendation pro-
vided by the algorithm in some patients.
Some limitations merit consideration when interpreting these find-
ings. First, our study was conducted in ED patients with symptoms
suggestive of AMI. Further studies are required to quantify the utility
of the ESC 0/1h-algorithms in patients with either a higher pre-test
probability (e.g. in a coronary care unit setting) or in patients with a
lower pre-test probability (e.g. in a general practitioner setting) for
AMI. Second, no specific sample size calculation was performed.
Although this secondary analysis from an ongoing multicentre study
is one of the largest ever performed, it still may have been underpow-
ered for some comparisons. Third, not all patients with acute chest
pain had a second set of laboratory measurements at 1 h. The most
common reasons for missing blood samples were logistic issues in
the ED that precluded blood draw around the 1h-window. However,
it is unlikely that the absence of these patients significantly influenced
our results. Fourth, although we used the most stringent method-
ology to adjudicate the presence or absence of AMI including central
adjudication by experienced cardiologists and serial measurements of
hs-cTn, we still may have misclassified a small number of patients.39
Fifth, our findings are specific to the two hs-cTn assays currently avail-
able for routine clinical care. Once other hs-cTn assays will become
available for clinical care, additional studies will need to derive and
validate a 0/1h-algorithm and examine whether our findings can be
generalized to them. Finally, we cannot generalize our findings to
patients with terminal kidney failure requiring dialysis, since they
were excluded from this study.
Conclusion
While the safety of the ESC 0/1h-algorithms remained very high,
increasing age significantly reduced overall efficacy, and the accuracy
of rule-in. Alternative slightly higher cut-off concentrations may be
considered for older patients, particularly if using hs-cTnI.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Kozhuharov N, Rentsch K, Miró Ò, López B, Martin-Sanchez FJ, Rodriguez-
Adrada E, Morawiec B, Kawecki D, Ganovská E, Parenica J, Lohrmann J, Kloos
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32. Rubini Giménez M, Hoeller R, Reichlin T, Zellweger C, Twerenbold R, Reiter M,
Moehring B, Wildi K, Mosimann T, Mueller M, Meller B, Hochgruber T, Ziller R,
Sou SM, Murray K, Sakarikos K, Ernst S, Gea J, Campodarve I, Vilaplana C, Haaf
P, Steuer S, Minners J, Osswald S, Mueller C. Rapid rule out of acute myocardial
infarction using undetectable levels of high-sensitivity cardiac troponin. Int J
Cardiol 2013;168:3896–3901.
33. Jaeger C, Wildi K, Twerenbold R, Reichlin T, Rubini Gimenez M, Neuhaus J-D,
Grimm K, Boeddinghaus J, Hillinger P, Nestelberger T, Singeisen H, Gugala M,
Pretre G, Puelacher C, Wagener M, Honegger U, Schumacher C, Moreno
Weidmann Z, Kreutzinger P, Krivoshei L, Freese M, Stelzig C, Dietsche S, Ernst
S, Rentsch K, Osswald S, Mueller C. One-hour rule-in and rule-out of acute
myocardial infarction using high-sensitivity cardiac troponin I. Am Heart J 2016;
171:92.e5–102.e5.
34. Hollander JE, Than M, Mueller C. State-of-the-art evaluation of emergency de-
partment patients presenting with potential acute coronary syndromes.
Circulation 2016;134:547–564.
35. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T
assay 99th percentile values from a common presumably healthy population. Clin
Chem 2012;58:1574–1581.
36. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W,
Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, Winkler K,
Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in
the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011;32:
1379–1389.
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